Adaptive Biotechnologies Corp (NAS:ADPT)
$ 6.145 -0.235 (-3.68%) Market Cap: 941.56 Mil Enterprise Value: 838.75 Mil PE Ratio: 0 PB Ratio: 4.20 GF Score: 81/100

Adaptive Biotechnologies Corp at Morgan Stanley Global Healthcare Conference (Virtual) Transcript

Sep 15, 2020 / 05:15PM GMT
Release Date Price: $45.95 (+7.94%)
Tejas Rajeev Savant
Morgan Stanley, Research Division - Equity Analyst

Hello, everyone. Good afternoon. Thanks for joining us today on day 2 of our healthcare conference. I'm Tejas Savant, and I cover the life science tools and diagnostics sector here at Morgan Stanley. I'm delighted to have Adaptive Biotechnologies join us today. And representing the company is Chad Robins, CEO. Thanks for joining us, Chad.

Before we begin, I just want to read a quick disclaimer. Please note the webcast is for Morgan Stanley's clients and appropriate Morgan Stanley employees only. The webcast is not for members of the press. If you are with the press, please disconnect and reach out separately. For important disclosures, please see morganstanley.com/researchdisclosures. And if you have any questions, please feel free to reach out to your sales rep.

Questions & Answers

Tejas Rajeev Savant
Morgan Stanley, Research Division - Equity Analyst

So with that, Chad, I mean, maybe just to kick things off, can you just go over, in your mind, sort of the value of the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot